Are blood cytokines reliable biomarkers of allergic disease diagnosis and treatment responses?

Radonjic-Hoesli, Susanne; Pavlov, Nikolay; Simon, Hans‐Uwe; Simon, Dagmar

doi:10.1016/j.jaci.2022.06.008

Cited by 9 publications

(15 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum levels of several cytokines, including Th2-cytokines such as interleukin (IL)-25, IL-4, IL-5, IL-13, and IL-33, are elevated in asthmatic adults and children compared to controls [ 66 ]. Increased serum levels of the chemokine CCL26/eotaxin-3 could differentiate moderate-to-severe asthma from healthy controls [ 67 ], and recent findings point out the ability of CCL17/TARC to predict type-2 eosinophilic asthma [ 68 ].…”

Section: Current Knowledge Of Circulating Biomarkersmentioning

confidence: 99%

“…In AD, Th2-chemokines such as CCL26/eotaxin-3 [ 103 , 104 ], CCL22/MDC [ 105 ], CCL18/PARC [ 100 , 106 ], CCL27/CTACK [ 107 ], and CCL17/TARC, have been more commonly found as blood biomarkers compared to Th2-cytokines [ 45 ], the latter of which is considered the most reliable biomarker for AD [ 66 ]. In fact, elevated serum TARC/CCL17 discriminated AD from healthy controls [ 102 , 108 , 109 ] and showed the best odds ratio (OR) when compared to eosinophil count, total IgE, serum IL-18, and lactate dehydrogenase (LDH) [ 110 ].…”

Section: Current Knowledge Of Circulating Biomarkersmentioning

confidence: 99%

“…Cytokines, as mediators of inflammation, have been extensively studied as inflammatory disease biomarkers. The blood levels of cytokines: IL-4, IL-13, IL-5, IL-6, IL-12p70, CD40ligand, IL-1α, and IL-17 distinguished EoE from non-EoE patients [ 159 ], but such changes could not be validated in subsequent studies [ 66 ]. Among cytokines, IL-5 has raised the highest interest given its key role in the proliferation, maturation, and differentiation of eosinophils within the bone marrow [ 160 ].…”

Section: Current Knowledge Of Circulating Biomarkersmentioning

confidence: 99%

“… Venn diagram showing overlapping circulating biomarkers for BA, AD, and EoE [ 16 , 19 , 47 , 48 , 49 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 65 , 66 , 67 , 68 , 83 , 84 , 85 , 92 , 93 , 94 , 99 , 100 , 101 , 102 , 103 , 107 , 108 , 114 , 118 , 122 , 123 , 136 , 137 , 138 , 139 , 144 , 148 , 150 , 151 , 152 , 153 , 154 , 157 , 160 , 165 ]. Created with Jvenn diagram viewer [ 173 ].…”

Section: Figurementioning

confidence: 99%

“… Venn diagram showing overlapping circulating biomarkers for BA, AD, BA-EVs, and AD-EVs [ 65 , 66 , 67 , 68 , 83 , 84 , 85 , 101 , 107 , 108 , 138 , 184 , 185 , 186 , 187 , 188 ]. Created with Jvenn diagram viewer [ 173 ].…”

Section: Figurementioning

confidence: 99%

See 4 more Smart Citations

Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles

Grueso-Navarro

Navarro

Laserna-Mendieta

et al. 2023

IJMS

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a chronic, Th2-inflammatory disease of the esophagus that can severely affect food intake. Currently, diagnosis and assessing response to treatment of EoE is highly invasive and requires endoscopy with esophageal biopsies. Finding non-invasive and accurate biomarkers is important for improving patient well-being. Unfortunately, EoE is usually accompanied by other atopies, which make it difficult to identify specific biomarkers. Providing an update of circulating EoE biomarkers and concomitant atopies is therefore timely. This review summarizes the current knowledge in EoE blood biomarkers and two of its most common comorbidities, bronchial asthma (BA) and atopic dermatitis (AD), focusing on dysregulated proteins, metabolites, and RNAs. It also revises the current knowledge on extracellular vesicles (EVs) as non-invasive biomarkers for BA and AD, and concludes with the potential use of EVs as biomarkers in EoE.

show abstract

Section: Current Knowledge Of Circulating Biomarkersmentioning

confidence: 99%

Section: Current Knowledge Of Circulating Biomarkersmentioning

confidence: 99%

Section: Current Knowledge Of Circulating Biomarkersmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles

Grueso-Navarro

Navarro

Laserna-Mendieta

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

An update on anaphylaxis and urticaria

Worm

Vieths

Mahler

2022

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

Turner,

Radzikowska,

Ferastraoaru

et al. 2024

Allergy

View full text Add to dashboard Cite

Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE‐mediated diseases and glioma. Allergic disease stems from a Th2‐biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour‐immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro‐Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult‐type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival.

show abstract

Are blood cytokines reliable biomarkers of allergic disease diagnosis and treatment responses?

Cited by 9 publications

References 89 publications

Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles

Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles

An update on anaphylaxis and urticaria

AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

Contact Info

Product

Resources

About